Respiratory

Pneumoconioses: silicosis, asbestosis, coal worker's, berylliosis

Clinical Overview and When to Suspect Pneumoconiosis

— Silicosis: sandblasting, mining, quarrying, stone cutting (especially engineered/artificial stone countertops — a re-emerging epidemic in young workers), foundry work, tunneling.

— Asbestosis: shipbuilding, insulation, brake lining, demolition, plumbing/pipefitting, Navy veterans pre-1980, roofers.

— Coal worker's pneumoconiosis (CWP): underground coal miners; resurgence in Appalachian miners with rapidly progressive disease.

— Berylliosis (chronic beryllium disease, CBD): aerospace, nuclear weapons, electronics, dental prosthetics, ceramics, alloy manufacturing.

— Upper-lobe predominant nodules + occupational dust → silicosis or CWP.

— Lower-lobe reticular changes + pleural plaques → asbestosis.

— Sarcoid-like granulomas + machinist/aerospace history → berylliosis.

Board pearl: A 35-year-old immigrant countertop fabricator with progressive dyspnea and upper-lobe nodules has accelerated silicosis until proven otherwise — ask about engineered quartz stone, the dominant emerging silicosis exposure in the US, and report to OSHA/NIOSH as a sentinel event.

Pneumoconioses are interstitial lung diseases caused by chronic inhalation of inorganic mineral dusts in the workplace; latency from first exposure is typically 10–30+ years (acute silicosis is the exception, occurring within months–5 years of heavy exposure).

Four high-yield entities for Step 3:

When to suspect: insidious dyspnea on exertion, nonproductive cough, and a compatible occupational history spanning years, with bilateral interstitial or nodular changes on chest imaging.

Key triggers in vignettes:

Many patients are asymptomatic at diagnosis and are detected on surveillance CXR — Step 3 expects you to obtain a detailed occupational and exposure history (Job-Exposure Matrix thinking): job titles, duration, materials handled, use of respirators, prior surveillance films.

Presentation Patterns and Key History

— Chronic (classic) silicosis: >10 years exposure, upper-lobe small (<10 mm) rounded nodules; mostly asymptomatic until PMF develops.

— Accelerated silicosis: 5–10 years of heavy exposure (engineered stone, sandblasting); faster decline, higher autoimmune/TB risk.

— Acute silicoproteinosis: months–5 years of intense exposure; PAP-like alveolar filling, rapidly fatal dyspnea and hypoxemia.

— Every job since age 16, with duration and specific tasks.

— Materials: silica, asbestos, coal, beryllium, hard metals.

— Respiratory protection used (fit-tested? consistently?).

— Prior B-reader CXR surveillance results.

— Secondhand exposures (family members, neighborhood).

— Smoking, TB exposure, prior IGRA/PPD.

— Connective tissue symptoms (silica → scleroderma, RA, ANCA vasculitis, lupus).

Key distinction: Asbestosis = lower-lobe reticular disease with pleural plaques; silicosis and CWP = upper-lobe nodular disease. PMF can complicate either silicosis or CWP and presents as conglomerate upper-lobe masses that mimic malignancy on imaging.

Silicosis presents in three temporal patterns — these are heavily tested:

Asbestosis: insidious dyspnea 15–35 years after exposure, dry cough, bibasilar crackles; ask about pre-1980 construction, shipyard, Navy, household/secondary exposure (spouse laundering work clothes), and smoking status (synergistic lung cancer risk).

CWP: simple CWP (small upper-lobe nodules, usually asymptomatic) vs complicated CWP / progressive massive fibrosis (PMF) with large (>1 cm) conglomerate masses, dyspnea, melanoptysis (black sputum).

Berylliosis: dyspnea, cough, fatigue, weight loss, arthralgias, sometimes skin granulomas — mimics sarcoidosis clinically and histologically. Ask about machining, dental labs, nuclear/aerospace work, even bystander/take-home exposure.

Targeted history checklist (Step 3 ambulatory framing):

Physical Exam Findings (and Hemodynamic Assessment when relevant)

— Bibasilar fine end-inspiratory "velcro" crackles (hallmark, present in >80% with established disease).

— Digital clubbing in up to 40% — should prompt evaluation for superimposed malignancy if new.

— Decreased breath sounds and dullness over pleural effusions (benign asbestos pleural effusion or mesothelioma).

— Often normal lung exam in simple disease.

— Diminished breath sounds, hyperresonance if emphysema coexists (especially in CWP miners).

— In PMF: bronchial breathing or dullness over conglomerate masses; cyanosis with advanced disease.

— Bibasilar crackles, occasional wheeze, palpable lymphadenopathy, skin granulomas at trauma/exposure sites; hepatosplenomegaly possible.

— Loud P2, fixed split S2, right parasternal heave, JVD with prominent a wave, hepatojugular reflux, peripheral edema, ascites.

— Resting hypoxemia or exertional desaturation on 6-minute walk test (6MWT) signals pulmonary hypertension risk.

— Sclerodermatous skin changes, Raynaud, RA joints → silica-associated autoimmunity (Erasmus/Caplan syndromes: silicosis or CWP + rheumatoid nodules).

— Erythema nodosum, uveitis → consider berylliosis vs sarcoidosis.

— Constitutional fevers + weight loss → rule out superimposed TB or nontuberculous mycobacteria, especially in silicosis.

Step 3 management: At every visit, document resting SpO2 and ambulatory SpO2 with 6MWT; a drop to ≤88% qualifies the patient for long-term supplemental O2 (Medicare criterion) and changes the entire long-term care plan, including air-travel counseling and pulmonary rehab referral.

Physical exam in pneumoconioses is often disproportionately mild relative to imaging; absence of findings does not exclude disease.

Asbestosis — the most exam-rich:

Silicosis / CWP:

Berylliosis:

Right heart / cor pulmonale screen (essential in advanced ILD):

Extrapulmonary clues:

Diagnostic Workup — Initial Labs / Imaging / ECG / Biomarkers

— Read by an ILO-certified B-reader (NIOSH program) using the ILO classification for profusion (0–3), shape (rounded p/q/r vs irregular s/t/u), and size of opacities.

— Silicosis/CWP: small rounded upper-lobe opacities; eggshell calcification of hilar/mediastinal lymph nodes is classic for silicosis (also seen in sarcoid).

— Asbestosis: lower-lobe reticular/linear opacities + pleural plaques (often calcified along diaphragm and lateral chest wall).

— PMF: conglomerate masses >1 cm, often upper-lobe, may cavitate.

— Silicosis: centrilobular and subpleural micronodules, upper-lobe predominant.

— Asbestosis: subpleural reticulation, honeycombing, traction bronchiectasis (UIP-like) + plaques.

— Berylliosis: peribronchovascular nodules with mediastinal/hilar adenopathy (sarcoid-like).

— Restrictive pattern with ↓TLC, ↓DLCO is typical; CWP often shows mixed or obstructive pattern from coexisting emphysema.

— DLCO is the most sensitive early marker.

Board pearl: Eggshell calcification of hilar nodes is classic for silicosis (and may be seen in CWP and sarcoidosis); when accompanied by upper-lobe nodules in a sandblaster, no biopsy is needed — diagnosis is made on history + imaging alone.

Diagnosis is clinico-radiologic: compatible exposure + characteristic imaging + exclusion of mimics; biopsy is rarely needed except for berylliosis or atypical features.

Chest X-ray (PA + lateral) — first-line screening tool:

High-resolution CT (HRCT) — much more sensitive; obtain if CXR equivocal or symptoms exceed CXR findings:

PFTs:

Adjuncts: ABG if hypoxemic; ECG (RAD, P pulmonale, RVH with cor pulmonale); CBC, BMP, ANA/RF/ANCA if autoimmune overlap suspected; IGRA in all silicosis patients.

Diagnostic Workup — Advanced or Confirmatory Studies

— Beryllium lymphocyte proliferation test (BeLPT) on blood or BAL lymphocytes — confirms beryllium sensitization.

— Diagnosis of chronic beryllium disease (CBD) requires: (1) exposure history, (2) positive BeLPT, and (3) non-caseating granulomas on lung biopsy (transbronchial or VATS).

— This distinguishes CBD from sarcoidosis when imaging looks identical.

— Asbestosis: ferruginous (asbestos) bodies — golden-brown, beaded, iron-coated fibers; >1 per mL of BAL or per cm² of lung tissue supports diagnosis.

— Silicosis: lymphocytic alveolitis; acute silicoproteinosis shows PAS-positive proteinaceous material (mimics PAP).

— Berylliosis: CD4-predominant lymphocytic alveolitis + positive BAL BeLPT.

— Atypical imaging, rapid progression, suspicion of malignancy, or to confirm berylliosis.

— Silicosis: silicotic nodules with whorled hyalinized collagen and birefringent particles under polarized light.

— CWP: coal macules with dust-laden macrophages around respiratory bronchioles ± focal emphysema.

— Asbestosis: diffuse interstitial fibrosis + asbestos bodies (required for histologic diagnosis).

Key distinction: Sarcoidosis vs chronic berylliosis — radiographically and histologically identical (non-caseating granulomas, hilar adenopathy); only a positive BeLPT distinguishes them. Always ask aerospace/nuclear/dental lab history before labeling "sarcoid."

Berylliosis is the exception that demands confirmatory immunologic testing:

Bronchoalveolar lavage (BAL):

Lung biopsy (transbronchial, cryobiopsy, or surgical) — reserve for:

Echocardiogram: screen for pulmonary hypertension when DLCO <50% predicted or unexplained dyspnea/desaturation.

TB testing: IGRA (preferred over PPD in silicosis due to anergy); treat latent TB infection in silicosis with full 9 months of isoniazid (or rifamycin-based regimen) — silicosis carries a ~3-fold increased risk of active TB.

Risk Stratification or First-Line Management Logic

1. Halt further exposure (most important intervention).

2. Treat complications and comorbidities.

3. Surveillance for TB, malignancy, and progression.

4. Symptom relief and rehabilitation.

5. Compensation and legal documentation.

— Mild: asymptomatic, normal/mild PFT changes, no hypoxemia → annual CXR, PFTs, IGRA.

— Moderate: dyspnea on exertion, restrictive PFTs with DLCO 40–60%, exertional desaturation → pulmonology referral, 6-month follow-up, pulmonary rehab.

— Severe: PMF, resting hypoxemia, cor pulmonale, FVC <50% → lung transplant evaluation (especially in young patients with accelerated silicosis from engineered stone).

— Notify OSHA/NIOSH; document via state workers' compensation system.

— Workplace controls: wet methods, local exhaust ventilation, fit-tested N95/PAPR, medical surveillance program.

— Permanent reassignment from exposure for berylliosis (any sensitization) and accelerated/acute silicosis.

— Asbestos + smoking → ~50× increased lung cancer risk (multiplicative synergy).

— Use varenicline or combination NRT + behavioral support; document at every visit.

Step 3 management: For any newly diagnosed pneumoconiosis: (1) remove from exposure, (2) test for latent TB with IGRA (especially silicosis), (3) update vaccines, (4) initiate smoking cessation, (5) refer to pulmonary rehab, and (6) file workers' compensation paperwork — these are the six high-yield ambulatory orders.

Pneumoconioses are irreversible and incurable; management goals are:

Severity stratification (drives follow-up cadence and referral):

Exposure removal:

Smoking cessation — non-negotiable:

Vaccinations: influenza annually, PCV20 (or PCV15 + PPSV23), COVID-19, RSV (age ≥60), Tdap.

Pulmonary rehab improves exertional capacity and quality of life even when PFTs do not improve.

Pharmacotherapy — First-Line Drug Regimen

— Oral corticosteroids (prednisone 0.5–1 mg/kg/day, tapered over months) for symptomatic CBD with declining PFTs or hypoxemia.

— Steroid-sparing agents: methotrexate, azathioprine, infliximab in refractory cases.

— Asymptomatic beryllium sensitization without granulomatous disease → surveillance only, no treatment.

— Bronchodilators (LABA/LAMA inhalers) if coexisting airflow obstruction, especially CWP miners with mixed obstruction.

— Inhaled corticosteroids only if asthma/COPD overlap with frequent exacerbations.

— Supplemental O2 for resting SpO2 ≤88% or PaO2 ≤55 mm Hg (or ≤89%/56–59 with cor pulmonale or polycythemia) — Medicare criteria.

— Opioids (low-dose morphine) for refractory dyspnea in end-stage disease.

— Isoniazid 300 mg/day × 9 months with pyridoxine, or

— Rifampin 600 mg/day × 4 months, or

— 3HP (INH + rifapentine weekly × 12 weeks) under DOT.

— Active TB in silicosis (silicotuberculosis): RIPE × 2 months, then INH + RIF for at least 7 months (extended continuation phase).

Board pearl: Corticosteroids do not alter outcomes in silicosis, asbestosis, or CWP and may worsen TB risk in silicosis — only berylliosis responds to steroids. Reflexively prescribing prednisone for "ILD" in a sandblaster is a wrong-answer trap.

No disease-modifying pharmacotherapy alters the natural history of silicosis, asbestosis, or CWP — emphasize this on exams. Treatment is supportive and complication-directed.

Berylliosis is the pharmacologic exception:

Symptom-directed therapy:

Latent TB treatment in silicosis (essential):

Avoid empiric antifibrotics: nintedanib is approved for progressive pulmonary fibrosis (PPF) phenotype and may be considered when a pneumoconiosis behaves progressively despite exposure cessation — specialist-driven decision.

Procedures / Revascularization / Invasive Management

— Indicated when FEV1 or FVC <40–50% predicted, severe hypoxemia, pulmonary hypertension, or rapidly progressive disease despite exposure removal.

— Particularly relevant in young patients with accelerated/acute silicosis from engineered stone — median age at transplant has been falling into the 30s–40s.

— Refer early to a transplant center; evaluation takes months and requires smoking cessation ≥6 months, BMI optimization, and psychosocial clearance.

— Whole lung lavage for acute silicoproteinosis — saline lavage of one lung at a time under general anesthesia to remove alveolar proteinaceous material.

— Pleurodesis or indwelling pleural catheter (IPC) for recurrent malignant or benign asbestos-related pleural effusions.

— Bronchoscopy with biopsy for suspicious nodules (rule out lung cancer, mesothelioma, TB).

— VATS pleurectomy/decortication or extrapleural pneumonectomy for selected mesothelioma (multimodal therapy).

— Asbestos exposure: increased risk of bronchogenic carcinoma (all histologies, especially with smoking) and mesothelioma (no smoking synergy).

— Silica: silica is a Group 1 IARC carcinogen for lung cancer — heightened vigilance for new nodules.

— Low-dose chest CT (LDCT) lung cancer screening still follows USPSTF criteria (age 50–80, ≥20 pack-years, current smoker or quit within 15 years) — occupational exposure alone does not currently qualify, but combined with smoking it should lower the threshold for diagnostic workup of any new symptom.

Step 3 management: A 38-year-old engineered stone fabricator with FVC 38% and resting hypoxemia → refer immediately to a lung transplant center while continuing O2, rehab, and exposure removal — do not wait for "maximum medical therapy" since none exists.

Lung transplantation is the only definitive intervention for end-stage pneumoconiosis:

Therapeutic procedures:

Surveillance for malignancy:

Cor pulmonale management: diuretics for volume overload, treat hypoxemia aggressively; pulmonary vasodilators only with confirmed PH and specialist input.

Special Populations — Elderly and Renal/Hepatic Impairment

— COPD, ischemic heart disease, heart failure with preserved EF, and lung cancer often coexist and confound the dyspnea workup.

— Distinguish ILD restriction from age-related decline using PFTs with DLCO and 6MWT rather than spirometry alone.

— Frailty and sarcopenia limit transplant candidacy; focus shifts to symptom control, advance care planning, and palliative care.

— Long-term prednisone for CBD in older adults: monitor for osteoporosis (DEXA + bisphosphonate or denosumab), hyperglycemia/steroid-induced diabetes, cataracts, hypertension, and PCP prophylaxis if dose ≥20 mg/day for ≥4 weeks.

— Avoid sedating opioids and benzodiazepines as first-line dyspnea relief; use cautiously and start low.

— Dose-adjust isoniazid metabolites (generally safe but monitor neuropathy), rifampin (no renal adjustment), ethambutol (reduce dose with CrCl <50), pyrazinamide (reduce with CrCl <30).

— Silica-associated nephropathy and ANCA-associated vasculitis can cause CKD/AKI; monitor UA, creatinine, and ANCA periodically in silicosis.

— INH, rifampin, pyrazinamide are hepatotoxic — obtain baseline LFTs and monitor monthly in older adults, alcohol users, or HCV/HBV coinfected; hold if ALT >3× ULN with symptoms or >5× ULN asymptomatic.

— Methotrexate (for refractory CBD) is contraindicated in significant hepatic disease.

CCS pearl: In an 80-year-old retired pipefitter with asbestosis and new dyspnea, order CBC, BNP, troponin, ECG, CT chest with contrast before assuming progression — superimposed CHF, MI, and pulmonary embolism are more common acute causes than ILD progression itself.

Elderly patients with pneumoconiosis usually have chronic, low-grade exposures from decades-old work (shipyards, coal mines, foundries pre-OSHA era) and present with overlapping comorbidities:

Polypharmacy considerations:

Renal impairment:

Hepatic impairment:

Vaccination prioritization is amplified in the elderly: PCV20, RSV, high-dose influenza, zoster, COVID boosters.

Special Populations — Pregnancy, Pediatrics, or Other Demographic Subgroups

— Pneumoconioses are rare in reproductive-age women historically, but engineered stone silicosis is changing this — increasing diagnoses in young female fabricators and partners of male workers (take-home exposure).

— Reduced lung volumes and increased oxygen demand in pregnancy may unmask previously subclinical restriction; obtain baseline PFTs and 6MWT in the 2nd trimester.

— Latent TB treatment in pregnancy with silicosis: INH + pyridoxine is preferred; defer rifapentine-based regimens; treat active TB with standard RIPE (pyrazinamide use in pregnancy is accepted by WHO/CDC despite limited safety data).

— Avoid methotrexate (teratogenic); prednisone is acceptable for CBD with risk-benefit discussion.

— Take-home exposure counseling: pregnant partners of workers should not handle work clothes; employer should provide on-site laundering.

— True occupational pneumoconiosis is uncommon in children but consider:

— Child labor exposures (international vignettes: small-scale mining, gem cutting).

— Secondary/bystander exposure to dusts brought home on parents' clothing — household asbestos and beryllium cases are well documented.

— Counsel families about decontamination at work, separate work shoes/clothes, and on-site showers.

— Heavy asbestos exposure in US Navy personnel (pre-1980 ship insulation), shipyard workers, and Gulf War-era burn pit exposures.

— File VA service-connected disability claims and document exposure thoroughly; PACT Act expands coverage for respiratory conditions in post-9/11 veterans.

Board pearl: A 28-year-old pregnant Latina woman with progressive dyspnea whose husband cuts quartz countertops should prompt household silica exposure evaluation — both partners need assessment, and workplace laundering practices must change.

Pregnancy:

Pediatrics:

Veterans:

Health equity: pneumoconioses disproportionately affect immigrant, low-wage, and non-unionized workers with limited access to surveillance — actively screen and provide language-concordant counseling.

Complications and Adverse Outcomes

— Progressive massive fibrosis (PMF): conglomerate upper-lobe masses >1 cm in silicosis or CWP; causes severe restriction and cor pulmonale.

— Respiratory failure and chronic pulmonary hypertension/cor pulmonale.

— Spontaneous pneumothorax from ruptured subpleural blebs (especially CWP with emphysema).

— Bronchiectasis distal to fibrotic distortion.

— Mycobacterial disease: silicosis confers ~3× increased risk of active TB and elevated risk of NTM (M. kansasii, MAC). Screen with IGRA at diagnosis and annually; treat LTBI aggressively.

— Recurrent bacterial pneumonia in advanced disease.

— Fungal superinfection (aspergilloma in old PMF cavities).

— Asbestos: bronchogenic carcinoma (all cell types; synergistic with smoking — ~50× risk), mesothelioma (latency 20–40 years; no smoking synergy), laryngeal and ovarian cancers.

— Silica (IARC Group 1 carcinogen): lung cancer risk independently elevated.

— Beryllium: lung cancer risk also elevated.

— Caplan syndrome: RA + rheumatoid nodules in lung in CWP or silicosis.

— Scleroderma (Erasmus syndrome), SLE, ANCA-associated vasculitis, anti-GBM (Goodpasture-like) disease, silica nephropathy.

— Benign pleural plaques (often calcified, lower-lateral chest wall and diaphragm).

— Benign asbestos pleural effusion (earliest manifestation, often within 10 years; diagnosis of exclusion).

— Diffuse pleural thickening with restriction.

— Rounded atelectasis ("comet tail sign" on CT — folded lung adjacent to thickened pleura) — benign but mimics malignancy.

Key distinction: Pleural plaques = marker of asbestos exposure, not disease, and do not cause symptoms or restriction; diffuse pleural thickening causes restriction and dyspnea. Mesothelioma is not caused by smoking and not prevented by smoking cessation.

Pulmonary complications:

Infectious complications:

Malignancy:

Autoimmune complications (silica-driven):

Pleural complications (asbestos):

When to Escalate Care — ICU, Consult, or Inpatient Triage

— Acute hypoxemic respiratory failure (PaO2/FiO2 <300) — consider superimposed pneumonia, PE, pneumothorax, CHF, or acute exacerbation of ILD.

— Massive hemoptysis (rule out TB, aspergilloma, lung cancer, mesothelioma).

— Tension pneumothorax (especially CWP with PMF and bullous disease).

— Acute silicoproteinosis with rapidly worsening hypoxemia — urgent pulmonology + consideration of whole lung lavage.

— Hypoxemic patients requiring titration of supplemental O2.

— Suspected silicotuberculosis or active TB → negative-pressure airborne isolation, sputum AFB ×3, NAAT, empiric RIPE while results pending; notify public health.

— New pleural effusion in asbestos-exposed patient: thoracentesis with cytology, ADA, cell count, protein, LDH, glucose, pH — rule out mesothelioma vs benign effusion.

— Pulmonology: all new diagnoses, ILD management, transplant referral.

— Occupational medicine: exposure documentation, workplace assessment, return-to-work decisions.

— Rheumatology: silica-associated autoimmune disease.

— Infectious disease: silicotuberculosis, NTM.

— Thoracic surgery / interventional pulmonology: biopsy, pleural disease, suspected mesothelioma.

— Palliative care: introduce early for symptom management; not synonymous with hospice.

— Cardiology: cor pulmonale, PH evaluation.

— Transplant pulmonology: any patient with FVC <50% or rapid decline.

— Report sentinel occupational disease to state health department, OSHA, and NIOSH.

— Active TB is reportable in all states.

CCS pearl: In a hypoxic engineered stone worker admitted with bilateral infiltrates, order: ABG, CXR, CT chest, sputum AFB ×3 with NAAT, IGRA, ECHO, BNP, HIV, and infectious workup — silicosis patients deteriorating acutely need TB ruled out before steroids are even contemplated.

ICU / acute escalation triggers:

Inpatient admission:

Specialist consultations (Step 3 likes structured referrals):

Public health reporting:

Key Differentials — Same-Category Causes

— Caused by organic antigens (bird droppings, moldy hay = Farmer's lung, hot tub lung); not an inorganic dust pneumoconiosis.

— Mid-upper lung centrilobular nodules, mosaic attenuation, air trapping on expiratory HRCT.

— BAL with marked lymphocytosis (CD4:CD8 reversed, <1) vs CBD which is CD4 predominant.

— Radiographically and histologically identical (non-caseating granulomas, bilateral hilar adenopathy).

— Only BeLPT distinguishes them — always ask exposure history before diagnosing sarcoid in machinists, dentists, aerospace workers.

— Both UIP pattern (basal subpleural reticulation, honeycombing).

— Asbestosis features pleural plaques and exposure history; IPF lacks both.

— IPF responds to antifibrotics (pirfenidone, nintedanib); asbestosis does not (though nintedanib is approved for PPF phenotype).

— Both upper-lobe nodular; coal macules vs silicotic nodules on histology; CWP nodules less fibrotic.

— CWP often coexists with silica exposure in mixed-dust pneumoconiosis.

— Both show alveolar PAS-positive material; silicoproteinosis requires recent intense silica exposure; PAP is autoimmune anti-GM-CSF antibody-mediated and is the textbook association.

Key distinction: When sarcoid imaging meets an aerospace, nuclear, or dental lab worker → order BeLPT before initiating steroids; this single test changes the diagnosis from sarcoidosis to chronic beryllium disease, with workers' compensation, disability, and surveillance implications.

Within the ILD/inorganic dust category, several conditions overlap and are tested side-by-side:

Hypersensitivity pneumonitis (HP):

Sarcoidosis vs chronic berylliosis:

Idiopathic pulmonary fibrosis (IPF) vs asbestosis:

Hard metal lung disease (cobalt-tungsten): giant cell interstitial pneumonia in carbide tool workers — separate entity.

Silicosis vs CWP:

Acute silicoproteinosis vs PAP (pulmonary alveolar proteinosis):

Talcosis (IV drug use, occupational): birefringent talc particles in pulmonary vasculature.

Key Differentials — Other-Category Causes

— Heart failure with preserved or reduced EF: Kerley B lines, cephalization, pleural effusions, elevated BNP, echo with LV dysfunction.

— Pulmonary embolism: acute pleuritic chest pain, hypoxemia, normal CXR or wedge infarct; CT-PA.

— Pulmonary hypertension (Group 1–5): dilated PA on CT, RV dilation on echo, RHC for confirmation.

— Tuberculosis: upper-lobe cavitary disease, mandatory rule-out in silicosis.

— NTM (MAC, M. kansasii): cavitary or nodular bronchiectatic disease, especially in older patients.

— Endemic fungi: histoplasmosis, coccidioidomycosis, blastomycosis — can cause nodules + adenopathy.

— Lymphangitic carcinomatosis: irregular interlobular septal thickening; primary breast, lung, GI, pancreas.

— Bronchogenic carcinoma and mesothelioma (especially asbestos).

— RA-ILD, scleroderma-ILD (NSIP > UIP), MDA5/anti-synthetase syndrome, GPA, EGPA, MPA — order ANA, RF, anti-CCP, ANCA, myositis panel when extrapulmonary features present.

— Amiodarone, methotrexate, nitrofurantoin, bleomycin, immune checkpoint inhibitors, radiation pneumonitis.

— Respiratory bronchiolitis-ILD (RB-ILD), desquamative interstitial pneumonia (DIP), Langerhans cell histiocytosis (upper-lobe cysts and nodules in smokers).

Board pearl: Always confirm a vignette's "interstitial pattern" with HRCT-defined distribution: upper-lobe nodular narrows to silicosis/CWP/sarcoid/berylliosis/HP/LCH; lower-lobe reticular with honeycombing narrows to IPF/asbestosis/CTD-ILD; mismatch should prompt rethinking the diagnosis.

Dyspnea + interstitial imaging in a worker has many non-pneumoconiosis explanations Step 3 will test:

Cardiopulmonary:

Infectious:

Malignancy:

Connective tissue diseases / vasculitis:

Drug-induced ILD:

Smoking-related ILD:

Eosinophilic lung disease: peripheral and BAL eosinophilia, often with asthma history.

Secondary Prevention / Discharge Medications / Long-Term Plan

— Silica PEL: OSHA permissible exposure limit is 50 µg/m³ (8-hour TWA); engineered stone fabrication often exceeds this.

— Asbestos PEL: 0.1 fiber/cc (8-hour TWA).

— Beryllium PEL: 0.2 µg/m³ (8-hour TWA), action level 0.1 µg/m³.

— Engineering controls (wet methods, local exhaust ventilation) > administrative controls > PPE (last line).

— Fit-tested respirators (N95, half-face, PAPR depending on exposure level).

— Inhalers if obstructive overlap (LABA/LAMA ± ICS).

— Supplemental O2 if criteria met; portable system for ambulation.

— Smoking cessation pharmacotherapy (varenicline + behavioral counseling).

— Vaccinations: influenza, PCV20, COVID, RSV, Tdap, zoster (age ≥50).

— LTBI treatment if IGRA positive (silicosis).

— Steroid + bone protection (calcium/vitamin D, bisphosphonate, PCP prophylaxis if applicable) in CBD.

— Document exposure history, imaging, PFTs; file workers' comp claim promptly (state-specific statutes of limitation).

— Black Lung Benefits Program for coal miners (federal).

— VA service connection for veterans with asbestos exposure.

— Encourage legal consultation for asbestos/mesothelioma trust funds.

— Counsel on take-home exposure; provide handouts in primary language.

— Screen exposed family members with CXR if take-home exposure suspected.

Step 3 management: At discharge from a new pneumoconiosis diagnosis, ensure six items are documented: (1) exposure removal letter, (2) workers' comp filing, (3) vaccines updated, (4) IGRA result and LTBI plan, (5) smoking cessation plan, (6) pulmonary rehab referral.

Primary intervention is permanent removal from further exposure — this changes the natural history more than any drug.

Workplace controls (employer responsibility, OSHA-enforced):

Discharge medication checklist (Step 3 high-yield):

Workers' compensation and legal:

Family/household:

Follow-Up, Monitoring Parameters, and Rehab/Counseling

— Stable simple pneumoconiosis: annual visit with CXR, spirometry with DLCO, 6MWT, symptom review, IGRA (silicosis) periodically.

— Moderate disease or recent change: every 3–6 months with PFTs, 6MWT, SpO2.

— Severe/transplant candidate: monthly–quarterly with pulmonology and transplant team coordination.

— PFTs: FVC, FEV1, TLC, DLCO — decline of FVC ≥10% or DLCO ≥15% over 1 year defines progressive pulmonary fibrosis (PPF) and may trigger antifibrotic consideration.

— 6MWT: distance and nadir SpO2; drop ≥4% or to ≤88% indicates exertional hypoxemia.

— Echo every 1–2 years to screen for PH if DLCO <50% or symptoms suggest it.

— Low-dose chest CT at clinician discretion for surveillance of suspicious nodules or progression; standard USPSTF LDCT lung cancer screening for eligible smokers.

— Annual IGRA in silicosis; mesothelioma surveillance not standardized but symptom-driven.

— Multidisciplinary program: exercise training, education, breathing techniques, nutritional support, psychosocial counseling.

— Improves dyspnea, exercise tolerance, and quality of life; covered by Medicare for symptomatic ILD.

— Smoking cessation (revisit every visit; multiplicative cancer risk with asbestos).

— Avoid further exposure: cannot return to dusty work even with respirator.

— Mental health: anxiety/depression common with chronic dyspnea; screen with PHQ-9, GAD-7.

— Advance care planning: introduce early, especially with progressive disease.

— Air travel: counsel on supplemental O2 needs if SpO2 ≤92% at rest.

Board pearl: A ≥10% FVC decline or ≥15% DLCO decline over 12 months in a patient with pneumoconiosis meets criteria for progressive pulmonary fibrosis (PPF) and is the threshold to consider nintedanib and accelerate transplant evaluation — even though baseline antifibrotics are not indicated.

Follow-up cadence (longitudinal, ambulatory framing):

Monitoring parameters:

Pulmonary rehabilitation:

Counseling:

Ethical, Legal, and Patient Safety Considerations

— Active TB (including silicotuberculosis) is reportable to public health in all 50 states.

— Many states have sentinel occupational disease reporting for silicosis, asbestosis, CBD, and PMF; report to state health department and NIOSH.

— OSHA investigations may follow reports of workplace exposure exceeding PELs.

— Patients have the right to know their occupational diagnosis and its implications for work, life expectancy, and family.

— Disclose mesothelioma and lung cancer risk to asbestos-exposed patients, including those with only pleural plaques.

— Patients diagnosed with pneumoconiosis must be informed that return to dusty work is contraindicated even with PPE.

— Document exposure history meticulously; this directly affects benefits eligibility.

— Statutes of limitation vary by state — file promptly after diagnosis.

— Federal Black Lung Benefits Act for coal miners; Energy Employees Occupational Illness Compensation Program (EEOICPA) for beryllium-exposed nuclear workers.

— Avoid conflicts of interest if serving as both treating physician and independent medical examiner.

— At hospital discharge, ensure clear documentation of LTBI status and exposure history in transfer summaries; missed silicotuberculosis diagnosis is a sentinel event.

— Reconcile home oxygen prescriptions and verify safe storage (no smoking near O2; fire risk).

— Physician cannot disclose diagnosis to employer without patient consent; however, fit-for-duty evaluations and OSHA medical surveillance reports have specific protocols.

— Pneumoconioses disproportionately affect immigrant, undocumented, and non-English-speaking workers; provide interpreter services and connect to community legal aid for compensation claims regardless of immigration status.

Step 3 management: A monolingual Spanish-speaking engineered stone worker newly diagnosed with silicosis requires: interpreter-mediated diagnosis disclosure, workers' comp filing (which protects workers regardless of immigration status in most states), workplace OSHA report, family screening for take-home exposure, and written restriction from further silica work — all coordinated at the index visit.

Mandatory reporting and surveillance:

Informed consent and disclosure:

Workers' compensation and legal:

Transition-of-care safety:

Confidentiality vs employer disclosure:

Health equity:

High-Yield Associations and Rapid-Fire Clinical Facts

— Eggshell calcification → silicosis (or CWP, sarcoid).

— Pleural plaques → asbestos exposure.

— PMF/conglomerate upper-lobe mass → silicosis or CWP.

— Honeycombing + plaques → asbestosis.

— Comet tail sign → rounded atelectasis (asbestos).

Board pearl: "Young countertop fabricator + upper-lobe nodules + rapidly progressive dyspnea" = engineered stone-associated accelerated silicosis — currently the most heavily tested emerging occupational lung disease on Step 3.

Silicosis — upper-lobe nodules, eggshell calcification, sandblasters, engineered quartz stone fabricators, miners; ↑TB risk 3×; IARC Group 1 lung carcinogen; Caplan syndrome with RA; Erasmus syndrome (silicosis + scleroderma); also associated with ANCA vasculitis, anti-GBM, SLE, and silica nephropathy.

Acute silicoproteinosis — months of intense exposure, alveolar PAS-positive material like PAP; treatment is whole lung lavage, exposure removal.

Asbestosis — lower-lobe reticular fibrosis + pleural plaques (calcified along diaphragm), ferruginous bodies on BAL/biopsy, latency 15–35 years, shipbuilders/insulators/Navy.

Asbestos-related cancers: bronchogenic carcinoma (×50 with smoking — multiplicative), mesothelioma (no smoking synergy, latency 20–40 years), laryngeal, ovarian; pleural plaques alone are markers of exposure, not disease.

CWP — coal miners, simple (small upper-lobe nodules) vs complicated (PMF); melanoptysis; Caplan syndrome; black lung benefits federal program.

Berylliosis — aerospace, nuclear, dental labs, electronics; BeLPT confirms; granulomas indistinguishable from sarcoid; responds to steroids; EEOICPA federal compensation.

Imaging buzzwords:

OSHA PELs: silica 50 µg/m³, asbestos 0.1 f/cc, beryllium 0.2 µg/m³.

No effective drug therapy for silicosis/asbestosis/CWP; berylliosis = steroids; PPF phenotype = nintedanib consideration.

TB workup: all silicosis → IGRA; treat LTBI; active TB requires extended 9-month therapy.

Lung transplant is the only definitive cure; refer early in accelerated silicosis.

Board Question Stem Patterns

Key distinction: When a stem features a young patient with rapidly progressive ILD and a stone-cutting occupation, the answer is almost always engineered stone silicosis with transplant referral, not idiopathic pulmonary fibrosis.

Stem pattern 1 — Engineered stone: 32-year-old male countertop fabricator, 7 years' exposure, progressive dyspnea, upper-lobe nodules with eggshell-calcified hilar nodes. Best next step? → IGRA for latent TB and remove from exposure; report to OSHA/NIOSH; refer to pulmonology and transplant center if severe.

Stem pattern 2 — Asbestos + smoker: 68-year-old retired pipefitter with 40-pack-year smoking history, dyspnea, bibasilar crackles, clubbing; CXR with lower-lobe reticular pattern and calcified diaphragmatic plaques. Diagnosis? → Asbestosis; counsel on multiplicative lung cancer risk and offer LDCT screening per USPSTF criteria.

Stem pattern 3 — Sarcoid mimic: 45-year-old aerospace engineer with dyspnea, hilar lymphadenopathy, non-caseating granulomas on biopsy. Next step? → BeLPT before treating as sarcoid; if positive, diagnose chronic beryllium disease and start prednisone.

Stem pattern 4 — PMF: Coal miner with large upper-lobe conglomerate masses, melanoptysis, severe restriction. Diagnosis? → Complicated CWP / PMF; file Black Lung benefits.

Stem pattern 5 — Pleural effusion in shipyard worker: 70-year-old with unilateral pleural effusion, asbestos exposure. Next step? → Thoracentesis with cytology, consider VATS pleural biopsy to evaluate for mesothelioma.

Stem pattern 6 — Caplan syndrome: Coal miner with seropositive RA and multiple peripheral lung nodules. Diagnosis? → Caplan syndrome.

Stem pattern 7 — Acute silicoproteinosis: Sandblaster after 18 months of intense exposure with rapidly progressive hypoxemia, alveolar filling pattern. Treatment? → Whole lung lavage + exposure removal.

Stem pattern 8 — Silicotuberculosis: Silicosis patient with new fever, weight loss, cavitary upper-lobe lesion. Next step? → Airborne isolation, sputum AFB/NAAT × 3, empiric RIPE, report to public health, treat for ≥9 months.

Stem pattern 9 — Take-home exposure: Spouse of stone fabricator with new respiratory symptoms → assess for household silica exposure and counsel on workplace decontamination.

One-Line Recap

— Silicosis: upper-lobe nodules + eggshell calcification; engineered stone is the modern epidemic; screen and treat latent TB; IARC Group 1 lung carcinogen; can cause autoimmune disease (Erasmus, Caplan, ANCA, SLE).

— Asbestosis: lower-lobe reticular fibrosis + pleural plaques; multiplicative lung cancer risk with smoking (~50×); mesothelioma unrelated to smoking with 20–40-year latency.

— CWP: simple (small upper-lobe nodules) → complicated (PMF with melanoptysis); Caplan syndrome; federal Black Lung benefits.

— Berylliosis: sarcoid mimic confirmed by BeLPT + non-caseating granulomas; responds to corticosteroids; aerospace/nuclear/dental lab exposure; EEOICPA compensation.

— Universal pneumoconiosis bundle: exposure removal, workers' compensation filing, OSHA/NIOSH reporting, IGRA, smoking cessation, vaccines (influenza/PCV20/COVID/RSV), pulmonary rehab, O2 if SpO2 ≤88%, early transplant referral for advanced disease, and antifibrotics (nintedanib) only when progressive pulmonary fibrosis criteria are met.

Step 3 management: Every new pneumoconiosis diagnosis triggers a six-item ambulatory order set — remove exposure, test for TB, vaccinate, counsel smoking cessation, refer to pulmonary rehab, and file workers' compensation — and every progression visit triggers reassessment of PFTs, 6MWT, echo, and transplant candidacy.

Pneumoconioses are irreversible occupational interstitial lung diseases whose management hinges on permanent exposure cessation, complication surveillance (especially TB in silicosis and malignancy in asbestos exposure), supportive care, and disability/compensation advocacy — with chronic beryllium disease being the lone steroid-responsive exception and lung transplantation the only definitive therapy for end-stage disease.

High-yield recap bullets: